Enhancing systemic anti-cancer treatment (SACT) capacity: implementing and using subcutaneous atezolizumab

Anna Olsson-Brown; Hala Ghoz; Mark Foulkes

doi:10.12968/bjon.2024.33.Sup17.S1

Enhancing systemic anti-cancer treatment (SACT) capacity: implementing and using subcutaneous atezolizumab

Anna Olsson-Brown
, Hala Ghoz
, Mark Foulkes

Cork University Dental School and Hospital

Advanced Clinical Practitioner in Lung Cancer
Macmillan Lead Cancer Nurse and Nurse Consultant (Acute Oncology)

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	S1-S13
Journal	British Journal of Nursing
Volume	33
Issue number	17
DOIs	https://doi.org/10.12968/bjon.2024.33.Sup17.S1
Publication status	Published - 1 Sept 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Humans
Antibodies, Monoclonal, Humanized/therapeutic use
Antineoplastic Agents/administration & dosage
Injections, Subcutaneous
United Kingdom
Lung Neoplasms/drug therapy
Neoplasms/drug therapy

Access to Document

10.12968/bjon.2024.33.Sup17.S1

Cite this

@article{e59b60798f2c40d58e2a019762247246,

title = "Enhancing systemic anti-cancer treatment (SACT) capacity: implementing and using subcutaneous atezolizumab",

keywords = "Humans, Antibodies, Monoclonal, Humanized/therapeutic use, Antineoplastic Agents/administration \& dosage, Injections, Subcutaneous, United Kingdom, Lung Neoplasms/drug therapy, Neoplasms/drug therapy",

author = "Anna Olsson-Brown and Hala Ghoz and Mark Foulkes",

year = "2024",

month = sep,

day = "1",

doi = "10.12968/bjon.2024.33.Sup17.S1",

language = "English",

volume = "33",

pages = "S1--S13",

journal = "British Journal of Nursing",

issn = "0966-0461",

publisher = "MA Healthcare Ltd",

number = "17",

}

TY - JOUR

T1 - Enhancing systemic anti-cancer treatment (SACT) capacity

T2 - implementing and using subcutaneous atezolizumab

AU - Olsson-Brown, Anna

AU - Ghoz, Hala

AU - Foulkes, Mark

PY - 2024/9/1

Y1 - 2024/9/1

KW - Humans

KW - Antibodies, Monoclonal, Humanized/therapeutic use

KW - Antineoplastic Agents/administration & dosage

KW - Injections, Subcutaneous

KW - United Kingdom

KW - Lung Neoplasms/drug therapy

KW - Neoplasms/drug therapy

U2 - 10.12968/bjon.2024.33.Sup17.S1

DO - 10.12968/bjon.2024.33.Sup17.S1

M3 - Article

C2 - 39311666

SN - 0966-0461

VL - 33

SP - S1-S13

JO - British Journal of Nursing

JF - British Journal of Nursing

IS - 17

ER -